Please use this identifier to cite or link to this item:
https://repository.unad.edu.co/handle/10596/61050Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.creator | Castillo , Martha | en |
| dc.creator | Mora Bautista, Ana Isabel | en |
| dc.creator | Oliveros , Ana lucía | en |
| dc.creator | Ramos , Gloria | en |
| dc.creator | Muñoz Zambrano , Maria Elena | en |
| dc.creator | Mora, Jonathan Andre | en |
| dc.date | 2023-12-16 | - |
| dc.identifier | https://hemeroteca.unad.edu.co/index.php/nova/article/view/7539 | - |
| dc.identifier | 10.22490/24629448.7539 | - |
| dc.description | Introduction. Thrombosis is associated with acquired risk factors or hypercoagulablestates. Antiphospholipid antibodies are found in infectious processes or associated with arterial or venous thrombosis. Among these is the lupus anticoagulant, which is conside-red an interference inhibitor because it prolongs phospholipid-dependent tests in vitro. Objectives. To relate the activity of factor XII and XI in patients with positive lupus anti-coagulant. Methodology. Of 55 plasmas, 34 met the inclusion criteria. Factors XII and XI were dosed by metric clot methods. Samples less than 50 Ul/dl are considered low factoractivity, to which the dilution test (parallelism) is performed. If a recovery greater than15% of the factor is evidenced, it is considered interference. If, on the contrary, the resultremains with little variation, it is confirmed. factor deficiency. Results. Of 34 dosages,79.4% (27/34) presented a decrease in factor XI. A dilution test was performed, and 100%recovery of factor XI was observed; Regarding the dosage of factor XII, 29.4% (10/34)presented values below 50 IU/dl and 70.6% (24/34) normal, did not recover in 22.2%(2/9) presenting deficit. Conclusions. The study of a prolonged PTT is carried out due tosuspicion of lupus anticoagulant or factor deficiency. The importance of the laboratory isthat every time a decreased coagulation factor is found, plasma dilution must be done todetermine if there is recovery of the factor or is a deficit of this. | en |
| dc.description | Introduction. Thrombosis is associated with acquired risk factors or hypercoagulable states. Antiphospholipid antibodies are found in infectious processes or associated with arterial or venous thrombosis. Among these is the lupus anticoagulant, which is conside- red an interference inhibitor because it prolongs phospholipid-dependent tests in vitro. Objectives. To relate the activity of factor XII and XI in patients with positive lupus anti- coagulant. Methodology. Of 55 plasmas, 34 met the inclusion criteria. Factors XII and XI were dosed by metric clot methods. Samples less than 50 Ul/dl are considered low factor activity, to which the dilution test (parallelism) is performed. If a recovery greater than 15% of the factor is evidenced, it is considered interference. If, on the contrary, the result remains with little variation, it is confirmed. factor deficiency. Results. Of 34 dosages, 79.4% (27/34) presented a decrease in factor XI. A dilution test was performed, and 100% recovery of factor XI was observed; Regarding the dosage of factor XII, 29.4% (10/34) presented values below 50 IU/dl and 70.6% (24/34) normal, did not recover in 22.2% (2/9) presenting deficit. Conclusions. The study of a prolonged PTT is carried out due to suspicion of lupus anticoagulant or factor deficiency. The importance of the laboratory is that every time a decreased coagulation factor is found, plasma dilution must be done to determine if there is recovery of the factor or is a deficit of this. | es |
| dc.format | application/pdf | - |
| dc.language | spa | - |
| dc.publisher | Universidad Nacional Abierta y a Distancia UNAD | es |
| dc.relation | https://hemeroteca.unad.edu.co/index.php/nova/article/view/7539/6515 | - |
| dc.rights | Derechos de autor 2023 Nova | es |
| dc.rights | https://creativecommons.org/licenses/by-nc-nd/4.0 | es |
| dc.source | NOVA Biomedical Sciences Journal; Vol. 21 No. 41 (2023): International Issue | en |
| dc.source | Revista Nova publicación científica en ciencias biomédicas; Vol. 21 Núm. 41 (2023): Número Internacional | es |
| dc.source | NOVA Ciências Biomédicas Publicação; v. 21 n. 41 (2023): Número Internacional | pt-BR |
| dc.source | 2462-9448 | - |
| dc.source | 1794-2470 | - |
| dc.subject | Antiphospholipid Syndrome | en |
| dc.subject | Dilution | en |
| dc.subject | Factor XII | en |
| dc.subject | Factor X | en |
| dc.subject | Anticoagulant | en |
| dc.subject | Lupus | en |
| dc.subject | Antiphospholipid syndrome | es |
| dc.subject | Dilution | es |
| dc.subject | Factor XII | es |
| dc.subject | Factor X | es |
| dc.subject | Anticoagulant | es |
| dc.subject | Lupus | es |
| dc.title | Importance of the dilution test in the dosageof coagulation factors XII and XI in plasma withpositive lupus anticoagulant | en |
| dc.title | Importance of the dilution test in the dosage of coagulation factors XII and XI in plasma with positive lupus anticoagulant | es |
| dc.type | info:eu-repo/semantics/article | - |
| dc.type | info:eu-repo/semantics/publishedVersion | - |
| dc.type | article | en |
| dc.type | article | es |
| dc.type | article | pt-BR |
| Appears in Collections: | Revista Nova | |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.